Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients

Clinical Transplantation

Volumn 11, Issue 6, 1997, Pages 633-639

  Ahsan, Nasimul ^a   Holman, Michael J ^a   Yang, Harold C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Cytomegalovirus; Oral ganciclovir; Renal transplantation

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; FEMALE; HUMAN; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; ORAL DRUG ADMINISTRATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SEROLOGIC TESTS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030721684     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Ho M. Advances in understanding cytomegalovirus infection after transplantation. Transpl Proc 1994: 26: 7.
2. METSELAAR HJ, WEIMAR W. Cytomegalovirus infection in renal transplantation. J Antimicrob Chemother 1989: 23(suppl E): 37.
3. WEIR MR, IRWIN BC, MATERS AW et al. Incidence of cytomegalovirus disease in cyclosporine-treated renal transplant recipients based on donor/recipient pretransplant immunity. Transplantation 1987: 43: 187.
4. BIA MJ, ANDIMAN W, GAUDIO J et al. Effect of treatment with cyclosporine versus azathioprine on incidence and severity of cytomegalovirus infection posttransplantation. Transplantation 1985: 40: 610.
5. HIBBARD PL, TOLKOFF-RUBIN NE, COSIMI AB et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992: 53: 68.
6. GANE E, SALIBA F, VALDECASA G et al. Efficacy and safety of oral ganciclovir in the prevention of CMV disease in liver transplant recipients: results of a multi center multinational clinical trial (presented at Annual meeting of Am Soc of Transplant Physicians and Surgeons, Dallas, Tx, May 1996).
7. SPECTOR SA, MCKINLE GF, LALEZARI JP et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med 1996: 334: 1491.
8. DREW WL, IVES D, LALEZARI JP et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis with AIDS. N Engl J Med 1995: 333: 615.
9. SERERAT MN, SCHIFANO JV, LAU P etal. Evaluation of cytomegalovirus (CMV) antibody screening tests for blood donors. Am J Clin Pathol 1986: 20: 763.
10. PAGE CV, WOLD AD, SMITH TF. Detection of cytomegalovirus infections in specimens other than urine by the shell vial assay and conventional tube cell culture. J Clin Microbiol 1987: 25: 755.
11. CRUMPACKER CS. Ganciclovir. N Engl J Med 1996: 335: 721.
12. PATEL R, SNYDMAN DR, RUBIN RH et al. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996: 61: 1279.
13. BALFOUR HH, CHACE BA, STAPLETON JT, SIMMONS RL, FRYD DS. A randomized placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989: 320: 1381.
14. GLOWACKI LS, SMAILL FM. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients - a meta-analysis. Clin Transpl 1994: 8: 10.
15. CHITWOOD KK, HEIM-DUTHOY KL, NEY AL, KASISKE BL. Questionable benefit of prophylactic acyclovir in renal transplant recipients at high risk for cytomegalovirus disease. Clin Transpl 1993: 7: 320.
16. BAILEY TC, ETTINGER NA, STROCH GA et al. Failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants. Am J Med 1993: 95: 273.
17. SNYDMAN DR, WERNER BG, HEINZE-LACEY B et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal transplant recipients. N Engl J Med 1987: 317: 1049.
18. KLETZMAYR J, KOTZMANN H, POPOW-KRAUPP T, KOVARIK J, KLAUSER R. Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients. J Am Soc Nephrol 1996: 7: 325.
19. LITTLER E, STUART AD, CREE MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral analogue ganciclovir. Nature 1992: 358: 160.
20. MERIGAN TC, RENLUND DG, KEAY S et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992: 326: 1182.
21. MARTIN S, MORRIS D, DYER PA, GOKAL R, MALLICK NP, JOHNSON RWG. The association between cytomegalovirus-specific antibodies, lymphocytotoxin antibodies, HLA-DR phenotype, and graft outcome in renal transplant recipient. Transplantation 1991: 51: 1303.
22. HARMANN P, DITTMAR R, TENSCHERT W et al. Association of HLA-A1, -A3, -B15 with CMV disease in cytomegalovirus IgG-positive recipients of renal allografts. Transpl Proc 1991: 23: 2660.
23. ROENHORST HW, TEGZESS AM, BEELEN JM, MIDDELDORP JM, THE TH. HLA-DRw6 as a risk factor for active cytomegalovirus but not for herpes simplex virus infection after renal allograft transplantation. Br Med J 1985: 291: 619.
24. SPECTOR SA, BUSCH DF, FOLLANSBEE S et al. Pharmacokinetics, safety, antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: phase I/II study. J Infect Dis 1995: 171: 1431.
25. ANDERSON RD, GRIFFY KG, JUNG D, DORR A, HULSE JD, SMITH RB. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. Clin Ther 1995: 17: 425.
26. TOCCI MJ, LIVELLI TJ, PERRY HC, CRUMPACKER CS, FIELD AK. Effects of nucleoside analog 2′-nor-2′-deoxy-guanosine on human cytomegalovirus replication. Antimicrob Agents Chemother 1984: 25: 247.
27. DREW WL, MINER R, SALEH E. Antiviral susceptibility testing of cytomegalovirus: criteria for detecting resistance to antivirals. Clin Diagn Virol 1993: 1: 179.
28. CYTOVENE®. Physicians Desk Reference 1996, Medical Economics Publishing, Montvale, NJ.
29. VAN DEN BERY AP, KLOMPMAKER IN, HOAGSMA EB et al. Evidence for an increased rate of bacterial infections in liver transplant patients with cytomegalovirus infection. Clin Transpl 1996: 10: 224.
30. CHATTERJEE SN, FIALA M, WEINER J, STEWART JA, STACEY B, WARNER N. Primary cytomegalovirus and opportunistic infections. J Am Med Assoc 1978: 240: 2446.
31. BOYCE NW, HAYES K, GEE D et al. Cytomegalovirus infection complicating renal transplantation and its relationship to acute transplant glomerulopathy. Transplantation 1988: 45: 706.
32. TENSCHERT W, DITTMER R, HARFMANN P et al. Vascular rejection of renal allografts linked to CMV IgG positive organ donor. Transpl Proc 1991: 23: 2641.
33. RICHARDSON WP, COLVIN RB, CHEESEMAN SH et al. Glomerulopathy associated with cytomegalovirus viremia in renal allografts. N Engl J Med 1981: 305: 57.